M. Kulyk & Associates’s Novo Nordisk NVO Stock Holding History

M. Kulyk & Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.6M	Buy	152,311 +71	+0%	+$3.36K	1.04%	33
2025 Q4	$7.75M	Buy	152,240 +22,231	+17%	+$1.14M	1.48%	25
2025 Q3	$7.21M	Buy	130,009 +52,687	+68%	+$3.08M	1.47%	26
2025 Q2	$5.34M	Buy	77,322 +11,425	+17%	+$777K	1.16%	31
2025 Q1	$4.58M	Buy	65,897 +62,715	+1,971%	+$5.18M	1.05%	37
2024 Q4	$274K	Buy	3,182 +119	+4%	+$12.9K	0.06%	85
2024 Q3	$365K	Sell	3,063 -1,573	-34%	-$210K	0.07%	79
2024 Q2	$662K	Sell	4,636 -900	-16%	-$119K	0.15%	59
2024 Q1	$711K	Sell	5,536 -324	-6%	-$38.6K	0.16%	60
2023 Q4	$606K	Buy	+5,860	New	+$580K	0.14%	65

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

M. Kulyk & Associates's NVO Position: Q1 2026 in Review

M. Kulyk & Associates increased its Novo Nordisk (NVO) stake by 0.05% in Q1 2026, buying an estimated $3.36K and bringing the position to 152,311 shares worth $5.6M. The position accounts for 1.04% of the portfolio, ranked #33.

M. Kulyk & Associates first reported a position in NVO in Q4 2023 and has held it in 10 quarters since. The position peaked at $7.75M in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

M. Kulyk & Associates held 152,311 shares of Novo Nordisk worth $5.6M as of Q1 2026.
M. Kulyk & Associates bought 71 Novo Nordisk shares in Q1 2026, an estimated $3.36K.
Novo Nordisk made up 1.04% of M. Kulyk & Associates's portfolio in Q1 2026, its #33 holding.
M. Kulyk & Associates first reported a position in Novo Nordisk in Q4 2023 and has held it in 10 quarters since.
M. Kulyk & Associates's Novo Nordisk position peaked at $7.75M in Q4 2025.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on M. Kulyk & Associates's 13F filing for Q1 2026, filed 6 May 2026.